Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-23-016675
Filing Date
2023-05-02
Accepted
2023-05-02 16:08:02
Documents
16
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A cyt-20221231.htm   iXBRL 10-K/A 90326
2 EX-31.1 cyt-ex31_1.htm EX-31 20173
3 EX-31.2 cyt-ex31_2.htm EX-31 20149
  Complete submission text file 0000950170-23-016675.txt   1721498

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20221231.xsd EX-101.SCH 53408
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cyt-20221231_def.xml EX-101.DEF 187019
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20221231_pre.xml EX-101.PRE 332269
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cyt-20221231_cal.xml EX-101.CAL 38699
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20221231_lab.xml EX-101.LAB 439316
10 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20221231_htm.xml XML 11140
Mailing Address 99 HAYDEN AVENUE BUILDING B, SUITE 450 LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE BUILDING B, SUITE 450 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

EIN.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-40499 | Film No.: 23878962
SIC: 2834 Pharmaceutical Preparations